Allosteric modulation of the solute carrier transporter SLC39A8 potentiates manganese and cadmium uptake
Authors:
- Kelly L. Damm-GanametKDKelly L. Damm-Ganamet
- Clara MoonCMClara Moon
- Alan D. WickendenAWAlan D. Wickenden
- Mark TichenorMTMark Tichenor
- Yunhui GeYGYunhui Ge
- Eduardo V. Mercado-MarinEMEduardo V. Mercado-Marin
- Brian ChiouBCBrian Chiou
- Ayla Manughian-PeterAMAyla Manughian-Peter
- Taraneh MirzadeganTMTaraneh Mirzadegan
- Jennifer D. VenableJVJennifer D. Venable
- Jennifer E. TowneJTJennifer E. Towne
Open Access
- 28 August 2025
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (21)
Abstract
Solute carrier (SLC) transporters govern the selective transport of diverse molecules across cell membranes, controlling fundamental metabolic and cellular processes. Despite genetic evidence implicating SLC transporters in a variety of human diseases, this family of proteins represents an underexplored target class for therapeutic drug discovery. Here, we discovered a selective potentiator of SLC39A8, a metal transporter associated with inflammatory bowel disease, schizophrenia, and cardiovascular and metabolic disorders. We conducted a drug repurposing screen, identifying efavirenz as a potentiator of manganese and cadmium uptake by SLC39A8 and subsequently generated structure-activity relationships to guide design of analogs. Computational pocket identification methodology and molecular dynamic simulations revealed a ligandable, cryptic pocket that, together with functional mutagenesis, indicated direct target engagement and allosteric modulation. Our findings demonstrate how the combination of experimental data and computational tools represents a powerful synergy that can enhance scientific outcomes. This integrated approach allowed for iterative feedback where insights from experiments informed the model refinements and computational predictions guided future experimental designs. Furthermore, our data established that SLC39A8 transporter activity can be increased pharmacologically, potentially opening avenues for SLC transporter drug discovery.Keywords
Funding Information
- National Institutes of Health (P30 DK043351)
- Leona M. and Harry B. Helmsley Charitable Trust (NA)
This publication has 80 references indexed in Scilit:
- Inhibitors of Human Divalent Metal Transporters DMT1 (SLC11A2) and ZIP8 (SLC39A8) from a GDB‐17 Fragment LibraryChemMedChem, 2021
- Genetic Disorders of Manganese MetabolismCurrent Neurology and Neuroscience Reports, 2019
- Inherited disorders of transition metal metabolism: an updateJournal of Inherited Metabolic Disease, 2017
- A SLC39A8 variant causes manganese deficiency, and glycosylation and mitochondrial disordersJournal of Inherited Metabolic Disease, 2016
- SLC39A8 Deficiency: A Disorder of Manganese Transport and GlycosylationThe American Journal of Human Genetics, 2015
- Autosomal-Recessive Intellectual Disability with Cerebellar Atrophy Syndrome Caused by Mutation of the Manganese and Zinc Transporter Gene SLC39A8The American Journal of Human Genetics, 2015
- A Call for Systematic Research on Solute CarriersCell, 2015
- Manganese transport disorder: Novel SLC30A10 mutations and early phenotypesMovement Disorders, 2015
- Mutations in SLC30A10 Cause Parkinsonism and Dystonia with Hypermanganesemia, Polycythemia, and Chronic Liver DiseaseThe American Journal of Human Genetics, 2012
- A hierarchical approach to all‐atom protein loop predictionProteins: Structure, Function, and Bioinformatics, 2004